On Monday, Celgene Corporation (NASDAQ:CELG)’s shares declined -0.29% to $111.00.
Celgene Corporation (CELG), declared two analyses of MCL-002 (SPRINT), its multi-center, open-label, phase II randomized trial comparing Revlimid® (lenalidomide) with investigators’ choice (IC) in patients with relapsed/refractory mantle cell lymphoma (MCL), were presented at the European Hematology Association annual congress.
In the study, 254 patients were randomized 2:1 to receive either REVLIMID (n=170) or single agent cytarabine, rituximab, gemcitabine, fludarabine or chlorambucil (n=84). The primary efficacy endpoint was progression free survival, defined as the time from randomization to disease progression or death due to any cause. Secondary endpoints, counting health-related quality of life (QoL) were analyzed in an exploratory manner.
The primary endpoint, median PFS was significantly improved for lenalidomide vs IC (8.7 vs 5.2 months; HR=0.61, P=0.004). A pre-specified exploratory analysis was presented and examined progression-free survival (PFS) in sub-groups based on prior therapies. Results examining the selected IC treatments in the study showed that REVLIMID offered a reduction in the risk of progression or death vs. each IC treatment. Contrast with lenalidomide, and taking into account the small number of patients per IC group, the risk reduction in PFS was 22% vs. rituximab (n=27), 56% vs. gemcitabine (n=20), 42% vs. fludarabine (n=18), 43% vs. chlorambucil (n=11), and 8% vs. cytarabine (n=8).
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)’s shares dropped -1.54% to $60.68.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) declared recently that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for reslizumab, the company’s investigational humanized monoclonal antibody (mAb) which targets interleukin-5 (IL-5), for the treatment of inadequately controlled asthma in adult and adolescent patients with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.
The BLA for reslizumab comprises data from Teva’s Phase III BREATH clinical trial program. The program compriseed of four separate placebo-controlled Phase III trials involving more than 1,700 adult and adolescent asthma patients with elevated blood eosinophils, whose symptoms were inadequately controlled with inhaled corticosteroid-based therapies. Results from these studies demonstrated that reslizumab, in comparison to placebo, reduced asthma exacerbation rates by at least half and offered noteworthyimprovement in lung function and other secondary measures of asthma control when added to an existing ICS-based therapy. Common adverse events in the reslizumab treatment group were comparable to placebo and comprised of worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache. Two anaphylactic reactions were stated and resolved following medical treatment at the study site.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
At the end of Monday’s trade, McDermott International (NYSE:MDR)‘s shares dipped -0.52% to $5.69.
McDermott International (MDR) declared that it has been awarded a contract by Mexican state-owned petroleum company – Pemex. Per the contract McDermott will perform engineering, procurement, construction, installation and pre-commissioning of the Ayatsil-C replacement jacket and related deck installation.
The company stated that this large brownfield contract would be added to its second-quarter backlog. The project is predictable to complete in the fourth quarter of 2016.
Administration at McDermott added that this is the fourth contract that it has been awarded for the Ayatsil field. Last year, the company delivered the Ayatsil-B drilling platform. Earlier this year, the firm accomplished the installation of the Ayatsil-A offshore jacket, deck and piles.
The Ayatsil field is located in the Bay of Campeche and is the biggest discovery for Pemex. The company has plans of developing the field using four platforms.
McDermott primarily serves the worldwide offshore oil and gas field developments. The company’s services comprise front-end design and detailed engineering in addition to fabrication and installation of offshore drilling and production facilities. The company also installs marine pipelines and subsea production systems.
Additionally, the company provides project administration and procurement services. It operates in most of the major offshore oil and gas producing regions, counting the U.S., Mexico, Canada, the Middle East, India, the Caspian Sea and the Asia Pacific.
McDermott International, Inc. operates as an engineering, procurement, construction, and installation company worldwide. The company operates through three segments: Asia Pacific, Americas, and the Middle East. It focuses on designing and executing offshore oil and gas projects.
Archer Daniels Midland Company (NYSE:ADM), ended its Monday’s trading session with -1.23% loss, and closed at $51.27.
Archer Daniels Midland Company (ADM) declared the following consideration to be paid in its formerly declared cash tender offers for up to $1,000,000,000 aggregate purchase price of its outstanding debentures (the “Debentures”).
The reference yield was determined by Barclays Capital Inc., BofA Merrill Lynch, Citigroup Global Markets Inc. and J.P. Morgan Securities LLC, the lead dealer managers for the tender offers, based on the bid-side price for the applicable U.S. Treasury security at 11:00 a.m., New York City time, as described in the Offer to Purchase dated June 1, 2015.
Holders who tender Debentures by 5:00 p.m., New York City time, on June 30, 2015, will be eligible to receive the applicable total consideration.
In addition, holders of Debentures accepted for purchase will be paid accrued interest to but not taking into account the settlement date. Withdrawal rights for the tender offers expired at 5:00 p.m., New York City time, on June 12, 2015.
The company will only purchase up to $1,000,000,000 aggregate purchase price of the Debentures in the tender offers, and the amount of each series of Debentures that will be purchased will be determined in accordance with the Acceptance Priority Levels set forth above and may be prorated as described in the Offer to Purchase. In addition, the aggregate principal amount of the 4.479% Debentures due 2021 (the “2021 Notes”) that may be purchased is subject to a maximum tender amount of $250,000,000 as described in the Offer to Purchase. Because, as formerly revealed, the principal amount of the 2021 Notes tendered already exceeds such maximum tender amount, any 2021 Notes that are purchased after applying the aggregate purchase price limitation and the Acceptance Priority Levels will be prorated.
Archer-Daniels-Midland Company procures, transports, stores, processes, and merchandises agricultural commodities and products. The company’s Oilseeds Processing segment originates, merchandises, crushes, and processes soybeans and soft seeds into vegetable oils and protein meals. It offers ingredients for the food, feed, energy, and industrial products industries; crude vegetable and salad oils; refined oils; oilseed protein meals; natural health and nutrition products, and other specialty food and feed ingredients; and cottonseed flour and cotton cellulose pulp.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
